跳至主要内容
临床试验/NCT05369182
NCT05369182
进行中(未招募)
不适用

Prospective Registry of Coronary Flow-Derived Indexes in Patients With Coronary Artery Disease

Samsung Medical Center7 个研究点 分布在 1 个国家目标入组 1,003 人2022年4月22日

概览

阶段
不适用
干预措施
Invasive physiologic assessment
疾病 / 适应症
Coronary Microvascular Disease
发起方
Samsung Medical Center
入组人数
1003
试验地点
7
主要终点
Patient-oriented composite outcomes (POCO)
状态
进行中(未招募)
最后更新
2个月前

概览

简要总结

Multicenter FLOW-CMD registry is a prospective, multi-center, registry study.

The aim of the study is to evaluate prognostic implications of coronary microvascular disease (CMD) in patients with ischemic heart disease (IHD) undergoing revascularization decision using FFR or other non-hyperemic pressure ratios.

详细描述

The diagnostic and therapeutic strategies in patients with coronary artery disease (CAD) have focused on identifying and alleviating both extent and severity of myocardial ischemia, as it is the most important prognostic fator. Thus, fractional flow reserve (FFR) has been a standard method for identifying ischemia-related epicardial coronary stenosis, accruing an abundance of clinical evidence on the benefit of FFR-guided treatment decisions. However, a high FFR value (\>0.80) does not necessarily imply freedom from future events. Indeed, clinical events still occur in patients who are deferred based on high FFR. The microvasculature is one of the main components of coronary circulatory system, and the presence of microvascular disease may contribute to clinical events in patients without epicardial coronary stenosis. In the cardiac catheterization laboratory, microvascular disease can be assessed using a pressure/temperature-sensor coronary wire or a Doppler wire. Previous studies have demonstrated the incremental prognostic implications of coronary flow reserve (CFR) and index of microcirculatory resistance (IMR) in patients with high FFR, and the recent European guidelines supported the importance of invasive physiologic assessment using CFR and IMR in patients with stable coronary artery disease. Furthermore, recent Expert Consensus Documents and the European Society of Cardiology guideline of Chronic Coronary Syndrome have underlined the importance of evaluating coronary microvascular disease (CMD) in patients with ischemic heart disease (IHD) and proposed an universal definition of CMD based on: 1) functionally non-obstructive CAD defined by a fractional flow reserve (FFR)\>0.80 and 2) impaired coronary microvascular function determined by abnormal CFR and/or microvascular resistance. Another important issue in contemporary practice is how to improve patient prognosis after percutaneous coronary intervention (PCI). Although PCI can induce secondary CMD originated from multiple mechanism associated with the procedure (e.g. distal embolization or endothelial dysfunction), and although secondary CMD also affects coronary circulatory function, there has been no previous evidence evaluating the incidence and prognosis of secondary CMD after successful PCI for epicardial coronary stenosis. Furthermore, both previous and recent trials demonstrated that intravascular imaging-guided PCI optimization has significantly better clinical outcomes than angiography-only guided PCI. However, these trials could not explain the exact mechanism underlying the potential benefit of intravascular imaging-guided PCI optimization for better clinical outcome, aside from a larger final stent area following intravascular imaging-guided PCI. Although the fundamental purpose of PCI is to resolve inducible myocardial ischemia originated from epicardial coronary stenosis, several studies have demonstrated that a substantial proportion of patients who underwent angiographically successful PCI had suboptimal post-PCI FFR or non-hyperemic pressure ratios, which are independently associated with worse clinical outcomes. Previous studies demonstrated that intravascular imaging devices could identify correctable cause of suboptimal post-PCI FFR. In this regard, it can be expected that intravascular imaging-guided PCI optimization would result in better post-PCI physiologic results such as higher post-PCI FFR and CFR, compared with angiography-only guided PCI. However, these issues have not been fully clarified. Regarding the prognostic impact of CMD, only limited data has been available on the prognostic implications of CMD defined by the universal definition among patients with IHD, especially in patients with insignificant epicardial coronary disease defined by FFR\>0.80. In addition, only one prospective study evaluated optical coherence tomography (OCT)-guided PCI for post-PCI FFR in patients with non-ST segment elevation myocardial infarction. None of prospective study evaluated potential physiologic benefit of intravascular imaging-guided PCI optimization using intravascular ultrasound (IVUS) or OCT in unselected patient population. Therefore, the primary objectives of the current multicenter prospective registry are to evaluate prognostic implications of CMD in patients with suspected IHD undergoing revascularization decision using FFR or other non-hyperemic pressure ratios and to evaluate the efficacy of intravascular imaging-guided optimization to enhance post-revascularization coronary circulatory function, compared with angiography-only guided revascularization in revascularized population.

注册库
clinicaltrials.gov
开始日期
2022年4月22日
结束日期
2027年12月31日
最后更新
2个月前
研究类型
Observational
性别
All

研究者

责任方
Principal Investigator
主要研究者

Joo Myung Lee

Professor

Samsung Medical Center

入排标准

入选标准

  • Subject must be ≥18 years
  • Patients suspected with IHD
  • Patients undergoing physiologic assessment (CFR, IMR, and FFR) for evaluation of severity of CAD
  • Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving invasive physiologic or imaging evaluation and he/she or his/her legally authorized representative provides written informed consent to any study related procedure.

排除标准

  • Cardiogenic shock (systolic blood pressure \<90mmHg or requiring inotropics to maintain blood pressure \>90mmHg) or cardiac arrest
  • Non-cardiac co-morbid conditions are present with life expectancy \<2 year (per site investigator's medical judgment).
  • Inability to undergo physiologic assessment (CFR, IMR, and FFR)
  • Pregnant or lactating women

研究组 & 干预措施

Total Population: Patients with CMD (CFR<2.0 and IMR≥25)

Among the enrolled patients, those who are diagnosed with CMD (CFR\<2.0, IMR≥25) in physiologic assessment.

干预措施: Invasive physiologic assessment

Total Population: Patients with preserved microvascular function (CFR≥2.0 OR IMR<25)

Among the enrolled patients, those who are with preserved microvascular function (CFR≥2.0 OR IMR\<25) in physiologic assessment.

干预措施: Invasive physiologic assessment

Revascularized Population: Patients treated by intravascular imaging-guided PCI optimization

Among patients who received PCI, patients whose PCI was optimized through intravascular imaging device (IVUS or OCT).

干预措施: Invasive physiologic assessment

Revascularized Population: Patients treated by intravascular imaging-guided PCI optimization

Among patients who received PCI, patients whose PCI was optimized through intravascular imaging device (IVUS or OCT).

干预措施: Intravascular imaging

Revascularized Population: Patients treated by angiography-only guided PCI

Among patients who received PCI, patients whose PCI was optimized through angiography-only.

干预措施: Invasive physiologic assessment

结局指标

主要结局

Patient-oriented composite outcomes (POCO)

时间窗: 1 year after last patient enrollment

a composite of all-cause death, MI, any repeat revascularization, or admission for heart failure

次要结局

  • All-cause death(1 year after last patient enrollment)
  • Target-vessel MI(1 year after last patient enrollment)
  • Cardiac death(1 year after last patient enrollment)
  • Non-target vessel MI(1 year after last patient enrollment)
  • Any MI(1 year after last patient enrollment)
  • Target vessel revascularization (clinically-driven or all)(1 year after last patient enrollment)
  • Non-target vessel revascularization (clinically-driven or all)(1 year after last patient enrollment)
  • Any repeat revascularization (clinically-driven or all)(1 year after last patient enrollment)
  • Admission for congestive heart failure(1 year after last patient enrollment)
  • Stroke (ischemic and hemorrhagic)(1 year after last patient enrollment)
  • Seattle Angina Questionnaire(Baseline, 1 year, and 2 year after patient enrollment)
  • Proportion of functionally optimized post-PCI results(Post-procedure)
  • Incidence of secondary CMD after PCI(Post-procedure)

研究点 (7)

Loading locations...

相似试验